CN1292746C - 含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物 - Google Patents

含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物 Download PDF

Info

Publication number
CN1292746C
CN1292746C CNB028120523A CN02812052A CN1292746C CN 1292746 C CN1292746 C CN 1292746C CN B028120523 A CNB028120523 A CN B028120523A CN 02812052 A CN02812052 A CN 02812052A CN 1292746 C CN1292746 C CN 1292746C
Authority
CN
China
Prior art keywords
composition
drug
celecoxib
compound
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028120523A
Other languages
English (en)
Chinese (zh)
Other versions
CN1516581A (zh
Inventor
P·高
T·黄
R·H·罗宾斯
J·M·鲍尔
J·E·吉多
A·M·布鲁格
A·卡里姆
F·哈桑
J·C·弗贝斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharMetrix Corp
Original Assignee
PharMetrix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1292746(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PharMetrix Corp filed Critical PharMetrix Corp
Publication of CN1516581A publication Critical patent/CN1516581A/zh
Application granted granted Critical
Publication of CN1292746C publication Critical patent/CN1292746C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB028120523A 2001-04-17 2002-04-12 含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物 Expired - Fee Related CN1292746C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28458901P 2001-04-17 2001-04-17
US60/284,589 2001-04-17
US35795902P 2002-02-19 2002-02-19
US60/357,959 2002-02-19

Publications (2)

Publication Number Publication Date
CN1516581A CN1516581A (zh) 2004-07-28
CN1292746C true CN1292746C (zh) 2007-01-03

Family

ID=26962690

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028120523A Expired - Fee Related CN1292746C (zh) 2001-04-17 2002-04-12 含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物

Country Status (21)

Country Link
US (5) US20030105144A1 (enExample)
EP (2) EP1494666A1 (enExample)
JP (2) JP2004529986A (enExample)
KR (1) KR20040012761A (enExample)
CN (1) CN1292746C (enExample)
AR (1) AR033466A1 (enExample)
AT (1) ATE370938T1 (enExample)
AU (1) AU2002254609B2 (enExample)
BR (1) BR0208947A (enExample)
CA (2) CA2444356A1 (enExample)
CZ (1) CZ20032793A3 (enExample)
DE (1) DE60221977T2 (enExample)
EA (1) EA006677B1 (enExample)
ES (1) ES2289139T3 (enExample)
IL (1) IL158200A0 (enExample)
MX (1) MXPA03009410A (enExample)
NO (1) NO20034627L (enExample)
NZ (1) NZ528716A (enExample)
PE (1) PE20021108A1 (enExample)
PL (1) PL367180A1 (enExample)
WO (2) WO2002102376A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646354A (zh) * 2015-05-19 2016-06-08 广州诺威生物技术有限公司 一种咪唑类化合物

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708574A (pt) * 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
US6849613B2 (en) 2001-08-29 2005-02-01 Kedar N. Prasad Multiple antioxidant micronutrients
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
US20040127537A1 (en) * 2002-06-26 2004-07-01 Gokarn Yatin R. Stable liquid parenteral parecoxib formulation
AU2003247622A1 (en) * 2002-06-27 2004-01-19 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2004112837A1 (ja) * 2003-05-23 2004-12-29 Hisamitsu Pharmaceutical Co., Inc. 非ステロイド系消炎鎮痛剤含有外用経皮製剤およびインターロイキン－１α生成抑制剤
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
AP2006003774A0 (en) 2004-04-07 2006-10-31 Univ Georgia Res Found Glucosamine and glucosamine / antiinflammatory mutual prodrugs, compositions, and methods
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
JP2008509899A (ja) * 2004-08-12 2008-04-03 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 胃腸管の炎症性疾患治療用の細胞特異的コンジュゲートの使用
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
WO2007058190A1 (ja) * 2005-11-16 2007-05-24 Tokai University Educational System 薬剤放出制御組成物および薬剤放出性医療器具
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
CA2651732C (en) * 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
US20080229477A1 (en) * 2007-03-22 2008-09-25 Mcgough Charles B Football glove for quarterbacks
US20100233272A1 (en) * 2007-11-15 2010-09-16 Leah Elizabeth Appel Dosage forms comprising celecoxib providing both rapid and sustained pain relief
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
CA2780177A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
CN102000018B (zh) * 2010-02-09 2012-07-04 浙江大学宁波理工学院 一种含塞来昔布的固体分散物及其制备方法和应用
EP2611442B1 (en) * 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
CN103384668B (zh) * 2010-09-03 2017-05-31 福马Tm有限责任公司 用于抑制nampt的化合物和组合物
BR112013019026A2 (pt) * 2011-02-01 2016-10-04 Astrazeneca Uk Ltd formulações farmacêuticas incluindo um composto amina
JP5973204B2 (ja) * 2011-03-30 2016-08-23 興和株式会社 カフェイン含有液状組成物及び該組成物を充填したカプセル剤
EP2780009A4 (en) * 2011-11-17 2015-05-06 Univ Colorado Regents METHOD AND COMPOSITIONS FOR IMPROVED DRUG RELEASE INTO EYE AND FORMULATIONS WITH EXTENDED RELEASE
CN103127520B (zh) * 2011-12-01 2016-05-04 天津键凯科技有限公司 聚乙二醇与坦索罗辛的结合物及其药物组合物
CN103372216B (zh) * 2012-04-26 2015-05-06 北京京卫燕康药物研究所有限公司 一种含有塞来昔布的固体药物组合物
JP6088760B2 (ja) 2012-07-10 2017-03-01 三菱瓦斯化学株式会社 過酸化水素の製造方法
WO2014012000A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
US10987365B2 (en) * 2012-10-01 2021-04-27 Gm Pharmaceuticals, Inc. Compositions and methods for the treatment of pain
WO2015011104A1 (en) * 2013-07-22 2015-01-29 Albert-Ludwigs-Universität Freiburg Polysaccharide hydrogels for injection with tunable properties
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
BR112017025527A2 (pt) * 2015-05-29 2018-08-07 Kiel Laboratories Inc preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe.
AU2016355236C1 (en) * 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US10722456B2 (en) * 2016-05-27 2020-07-28 Dr. Reddy's Laboratories Ltd Oral composition of celecoxib for treatment of pain
US11096924B2 (en) 2016-09-07 2021-08-24 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and PGE2 antagonists
CN111848538A (zh) * 2019-04-25 2020-10-30 山东墨海生物科技有限公司 一种帕瑞昔布钠杂质的合成方法
CN112409283A (zh) * 2020-11-24 2021-02-26 苏州璞正医药有限公司 一种帕瑞昔布衍生物及其制备方法和应用
EP4267132A1 (en) 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain
JP2025514339A (ja) * 2022-04-28 2025-05-02 ランバン メッド－テック リミテッド 疾患の処置に使用するための組成物
CN115453011A (zh) * 2022-10-19 2022-12-09 天和药业股份有限公司 一种地拉考昔含量检测方法
CN115754084B (zh) * 2022-11-30 2024-07-12 天和药业有限公司 一种吗伐考昔的分析方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240646A (zh) * 1998-01-12 2000-01-12 灵药生物技术有限公司 非甾体抗炎药物的可注射药物组合物
WO2001022969A2 (en) * 1999-09-27 2001-04-05 American Cynamid Company Vasopressin agonist formulation and process
WO2001022942A1 (en) * 1999-09-27 2001-04-05 American Cyanamid Company Pharmaceutical carrier formulation
WO2001022945A1 (en) * 1999-09-27 2001-04-05 American Cyanamid Company Vasopressin antagonist formulation and process

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644449A (en) 1969-03-27 1972-02-22 Texaco Inc Bis(perfluoroalkyl) nitroxide mercuride
US4146721A (en) 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3901908A (en) 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
DE2129012A1 (de) 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
US3984431A (en) 1972-03-15 1976-10-05 Claude Gueremy Derivatives of pyrazole-5-acetic acid
FR2248027B2 (enExample) 1973-10-18 1977-09-09 Serdex
US4302461A (en) 1979-08-09 1981-11-24 E. I. Du Pont De Nemours And Company Antiinflammatory 5-substituted-2,3-diarylthiophenes
CA1128526A (en) 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
US5169857A (en) 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
US4372964A (en) 1980-10-30 1983-02-08 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-1H-imidazole-2-methanols
US4381311A (en) 1980-12-29 1983-04-26 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-(polyhalomethyl)-2-thiophenemethanols
US4427693A (en) 1981-08-05 1984-01-24 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines
US4590205A (en) 1982-03-03 1986-05-20 E. I. Du Pont De Nemours And Company Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
US4820827A (en) 1982-03-03 1989-04-11 E. I. Du Pont De Nemours And Company 2,3-diaryl-5-bromothiophene compounds of use for the treatment of inflammaton and dysmenorrhea
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
ZA826501B (en) 1982-09-06 1984-04-25 Du Pont Anti-hypertensive imidazole derivative
US4533666A (en) 1983-06-22 1985-08-06 Eli Lilly And Company 6-Phenyl-2,3-bis-(4-methoxyphenyl)-pyridine derivatives having anti-inflammatory activity
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US4632930A (en) 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4805354A (en) * 1986-05-07 1989-02-21 General Electric Company Apparatus and method for lapping an edge surface of an object
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0272704A3 (en) 1986-12-26 1990-11-22 Sanwa Kagaku Kenkyusho Co., Ltd. Use of pyrazole derivatives in the treatment of immunity diseases and nephropathy
US5051518A (en) 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
JP2590124B2 (ja) 1987-08-12 1997-03-12 国際試薬株式会社 水溶性テトラゾリウム化合物およびその化合物を用いる還元性物質の測定方法
CA2003283A1 (en) 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
DE3903993A1 (de) 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH04134077A (ja) 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
JPH04277724A (ja) 1991-03-06 1992-10-02 Sumitomo Electric Ind Ltd 有機非線形光学材料
WO1992015570A1 (en) 1991-03-07 1992-09-17 Hisamitsu Pharmaceutical Co., Inc. Novel diphenylthyazole derivative
US5399577A (en) 1991-05-01 1995-03-21 Taiho Pharmaceutical Co., Ltd. Isoxazole derivatives and salts thereof
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
AU3592493A (en) 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH05323522A (ja) 1992-05-20 1993-12-07 Fuji Photo Film Co Ltd 黒白ハロゲン化銀写真感光材料の処理方法
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
CA2152792C (en) 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AU684316B2 (en) 1993-10-15 1997-12-11 Shionogi & Co., Ltd. Oxazolinone derivative having intracellular phospholipase A2 inhibitor activity
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
ATE233245T1 (de) 1993-11-30 2003-03-15 Searle & Co Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5401765A (en) 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en) 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CZ291659B6 (cs) 1995-11-17 2003-04-16 Warner-Lambert Company Sulfonamidové inhibitory matricových metaloproteináz
CN100413859C (zh) 1996-01-23 2008-08-27 盐野义制药株式会社 磺化的氨基酸衍生物及含有它的金属蛋白酶抑制剂
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
ES2125161B1 (es) 1996-03-21 1999-11-16 Grupo Farmaceutico Almirall S Nuevos derivados de 2-(3h)-oxazolona.
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
BR9708574A (pt) * 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
KR20000029784A (ko) * 1996-08-02 2000-05-25 나까도미 히로다카 경구제제용캡슐과경구캡슐제제
KR20000057444A (ko) 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 심기능부전 및 심실확장의 치료 및 예방 방법
US5770215A (en) * 1997-01-06 1998-06-23 Moshyedi; Emil Payman Multivitamin/vascular occlusion inhibiting composition
ES2131015B1 (es) 1997-09-12 2000-03-01 Almirall Prodesfarma Sa Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas.
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
AU1378699A (en) 1997-11-03 1999-05-24 Medlogic Global Corporation Cyanoacrylate polymer compositions comprising an antimicrobial agent
WO1999059583A1 (en) * 1998-05-18 1999-11-25 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
ES2137138B1 (es) 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
US7223772B1 (en) 1998-11-03 2007-05-29 Smithkline Beecham Corporation Pyrazolopyridine derivatives as selective cox-2 inhibitors
JP2002533404A (ja) 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
BRPI0011172B8 (pt) 1999-04-14 2021-05-25 Pacific Corp derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
PL351374A1 (en) 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
NZ515711A (en) 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
CA2381895A1 (en) 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
ES2222919T3 (es) 1999-08-27 2005-02-16 Abbott Laboratories Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
US6323226B1 (en) 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
GB9930075D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
GB0002312D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
EP1274425A1 (en) * 2000-04-18 2003-01-15 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor
WO2001083464A1 (en) 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
CN1199956C (zh) 2000-04-21 2005-05-04 盐野义制药株式会社 具有抗癌作用的噁二唑衍生物
WO2001083461A1 (en) 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Thiazole and oxazole derivatives
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
CN1245386C (zh) 2000-06-12 2006-03-15 卫材株式会社 1,2－二氢吡啶化合物及其制备方法和用途
US20020077328A1 (en) * 2000-07-13 2002-06-20 Fred Hassan Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
WO2002009759A2 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
IN191090B (enExample) 2000-08-29 2003-09-20 Ranbanx Lab Ltd

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1240646A (zh) * 1998-01-12 2000-01-12 灵药生物技术有限公司 非甾体抗炎药物的可注射药物组合物
EP1002531A1 (en) * 1998-01-12 2000-05-24 Panacea Biotec Limited A water-miscible composition of non-steroidal antiinflammatory drugs
WO2001022969A2 (en) * 1999-09-27 2001-04-05 American Cynamid Company Vasopressin agonist formulation and process
WO2001022942A1 (en) * 1999-09-27 2001-04-05 American Cyanamid Company Pharmaceutical carrier formulation
WO2001022945A1 (en) * 1999-09-27 2001-04-05 American Cyanamid Company Vasopressin antagonist formulation and process

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646354A (zh) * 2015-05-19 2016-06-08 广州诺威生物技术有限公司 一种咪唑类化合物
CN105646354B (zh) * 2015-05-19 2018-04-10 广州诺威生物技术有限公司 一种咪唑类化合物

Also Published As

Publication number Publication date
NZ528716A (en) 2005-04-29
AU2002254609B2 (en) 2007-06-21
ATE370938T1 (de) 2007-09-15
US20040002522A1 (en) 2004-01-01
JP2004526765A (ja) 2004-09-02
EP1494666A1 (en) 2005-01-12
CZ20032793A3 (cs) 2004-11-10
HK1068278A1 (en) 2005-04-29
PE20021108A1 (es) 2003-01-16
WO2002102376A1 (en) 2002-12-27
US20050032852A1 (en) 2005-02-10
DE60221977T2 (de) 2008-05-15
IL158200A0 (en) 2004-05-12
ES2289139T3 (es) 2008-02-01
DE60221977D1 (de) 2007-10-04
EP1379513A1 (en) 2004-01-14
AR033466A1 (es) 2003-12-17
JP2004529986A (ja) 2004-09-30
NO20034627L (no) 2003-12-12
EP1379513B1 (en) 2007-08-22
EA006677B1 (ru) 2006-02-24
WO2002102376A8 (en) 2003-04-24
MXPA03009410A (es) 2004-01-29
KR20040012761A (ko) 2004-02-11
CN1516581A (zh) 2004-07-28
US20050112197A1 (en) 2005-05-26
BR0208947A (pt) 2004-10-19
NO20034627D0 (no) 2003-10-16
CA2444267A1 (en) 2002-10-24
EA200301018A1 (ru) 2004-06-24
CA2444356A1 (en) 2002-12-27
WO2002083655A1 (en) 2002-10-24
US20030105144A1 (en) 2003-06-05
PL367180A1 (pl) 2005-02-21
US20030055012A1 (en) 2003-03-20
US6613790B2 (en) 2003-09-02
US6809111B2 (en) 2004-10-26

Similar Documents

Publication Publication Date Title
CN1292746C (zh) 含具有氨基磺酰基的活性化合物、聚乙二醇和抗氧化剂的口服传递的药用组合物
CN1305470C (zh) 制备细自乳化的药物组合物的方法
CN100335136C (zh) 具有降低的药物结晶趋势的药物组合物
US8362062B2 (en) Pharmaceutical compositions with improved dissolution
AU2002254609A1 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (COX-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
CN1512882A (zh) 包含cox-2抑制剂的可稀释配制的胃肠外组合物
CN1547474A (zh) 含选择性环加氧酶-2抑制剂及一元醇的可渗透皮肤的组合物
KR20040018355A (ko) 낮은 수용해도 약물(ｃｏｘ-2 저해제), 용매, 지방산 및유기아민을 포함하는 경구 송달가능한 약학적 조성물
US20060052432A1 (en) Pharmaceutical compositions with improved dissolution
CN101060832A (zh) 非水液体肠胃外醋氯芬酸配方
WO2004061433A1 (en) Pharmaceutical compositions with improved dissolution
HK1068278B (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group, a polyethylene glycol and an antioxidant
HK1076382B (en) Process for preparing a finely self-emulsifiable pharmaceutical composition
CA2511881C (en) Pharmaceutical compositions comprising a sodium salt of celecoxib with improved dissolution
EP2339328A2 (en) Pharmaceutical co-crystal compositions of celecoxib
ZA200307576B (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (Cox-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant.
HK1065959B (en) Pharmaceutical composition having reduced tendency for drug crystallization
CN1433308A (zh) 能迅速开始治疗作用的环氧合酶－2抑制剂组合物
HK1067554A (en) Reconstitutable parenteral composition containing a cox-2 inhibitor
HK1059561A (en) Cycloxooxygenase-2 inhibitor compositions havign rapid onset of therapeutic effect
HK1056844A (en) Use of a celecoxib composition for fast pain relief
HK1080717B (en) Pharmaceutical compositions with improved dissolution

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068278

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070103